{ "title": "Liraglutide (public encyclopedia provenance reconstruction)", "therapyArea": "Metabolic", "finding": "Reconstructed from 20 public encyclopedia revisions showing article evolution", "provenance": { "sourceArtifacts": [ { "artifactId": "wp-revision-192122871", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192122871)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192122871", "version": "192122871", "publicationDate": "", "effectiveDate": "", "retrievalUrl": "", "summary": "Article revision 192122871", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192123901", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192123901)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192123901", "version": "192123901", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192123901", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192127740", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192127740)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192127740", "version": "192127740", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192127740", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192131328", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192131328)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192131328", "version": "192131328", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192131328", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192132071", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192132071)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192132071", "version": "192132071", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192132071", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192132994", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192132994)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192132994", "version": "192132994", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192132994", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192133935", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192133935)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192133935", "version": "192133935", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192133935", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192134504", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192134504)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192134504", "version": "192134504", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192134504", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192135498", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192135498)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192135498", "version": "192135498", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192135498", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192138024", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192138024)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192138024", "version": "192138024", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192138024", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192138737", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192138737)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192138737", "version": "192138737", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192138737", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192139472", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192139472)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192139472", "version": "192139472", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192139472", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192140127", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192140127)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192140127", "version": "192140127", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192140127", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192141705", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192141705)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192141705", "version": "192141705", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192141705", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192142022", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192142022)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192142022", "version": "192142022", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192142022", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192142806", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192142806)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192142806", "version": "192142806", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192142806", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192142942", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192142942)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192142942", "version": "192142942", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192142942", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192143244", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192143244)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192143244", "version": "192143244", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192143244", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192143776", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192143776)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192143776", "version": "192143776", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192143776", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" }, { "artifactId": "wp-revision-192145258", "artifactType": "other", "issuer": "Wikipedia", "title": "Liraglutide (revision 192145258)", "stableIdentifier": "https://en.wikipedia.org/w/index.php?title=Liraglutide&oldid=192145258", "version": "192145258", "publicationDate": "2008-02-17", "effectiveDate": "2008-02-17", "retrievalUrl": "", "summary": "Article revision 192145258", "contentHash": "", "ingestedAt": "2026-06-19", "epistemicStatus": "directly-observed" } ], "sourceAssertions": [ { "assertionId": "assert-following-subcutaneous-administration-the-protracted-action-", "artifactId": "wp-revision-192123901", "exactText": "Following subcutaneous administration, the protracted action profile is based on three mechanisms: binding to albumin and enzymatic stability towards the DPP-IV enzyme both of which result in a long plasma half-life, and self-association which results in a slow absorption", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-liraglutide-action-is-mediated-via-a-specific-interaction-wi", "artifactId": "wp-revision-192123901", "exactText": "Liraglutide action is mediated via a specific interaction with GLP-1 receptors, leading to an increase in cAMP", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c", "artifactId": "wp-revision-192123901", "exactText": "Liraglutide stimulates insulin secretion and improves beta-cell function in a glucose-dependent manner", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-simultaneously-liraglutide-lowers-inappropriately-high-gluca", "artifactId": "wp-revision-192123901", "exactText": "Simultaneously, liraglutide lowers inappropriately high glucagon secretion, also in a glucose dependent manner", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-thus-when-blood-glucose-is-high-insulin-secretion-is-stimula", "artifactId": "wp-revision-192123901", "exactText": "Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-liraglutide-does-not-impair-glucagon-response-during-hypogly", "artifactId": "wp-revision-192123901", "exactText": "Liraglutide does not impair glucagon response during hypoglycaemia", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-furthermore-the-mechanism-of-blood-glucose-lowering-involves", "artifactId": "wp-revision-192123901", "exactText": "Furthermore, the mechanism of blood glucose lowering involves a minor decrease in gastric emptying", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-liraglutide-reduces-body-weight-and-body-fat-mass-by-a-mecha", "artifactId": "wp-revision-192123901", "exactText": "Liraglutide reduces body weight and body fat mass, by a mechanism of reduced hunger and lowered energy intake", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe", "artifactId": "wp-revision-192123901", "exactText": "Liraglutide has been shown to delay the progression of diabetes in animal models of pre-diabetes", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-liraglutide-has-been-shown-in-vitro-to-be-a-potent-agent-for", "artifactId": "wp-revision-192123901", "exactText": "Liraglutide has been shown in vitro to be a potent agent for specific stimulation of beta-cell proliferation and prevention of both cytokine and free fatty acid induced apoptosis", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-in-vivo-liraglutide-increases-insulin-biosynthesis-and-beta-", "artifactId": "wp-revision-192123901", "exactText": "In vivo, liraglutide increases insulin biosynthesis, and beta-cell mass in diabetic animal models", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-references-http-www-glucagon-com-liraglutide-htm", "artifactId": "wp-revision-192131328", "exactText": "References:\n[http://www.glucagon.com/liraglutide.htm]", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm", "artifactId": "wp-revision-192132071", "exactText": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "artifactId": "wp-revision-192133935", "exactText": "In a phase 2 trial enrolling 165 patients with type 2 diabetes, 14 weeks of liraglutide monotherapy reduced the estimated mean HbA1c values by 1.74% vs placebo from an average baseline of 8.5% and FPG by 3.4 mmol/l without hypoglycemic episodes", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-a-dose-dependent-decrease-in-body-weight-was-observed-with-a", "artifactId": "wp-revision-192133935", "exactText": "A dose-dependent decrease in body weight was observed, with a mean weight loss of 3.0 kg in the 1.9-mg liraglutide group", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-significant-improvements-in-indices-of-beta-cell-function-an", "artifactId": "wp-revision-192133935", "exactText": "Significant improvements in indices of beta cell function and blood pressure were also found along with a decrease in fasting glucagon with lira 1.9 mg", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-the-lead-programme-evaluated-the-efficacy-and-safety-of-lira", "artifactId": "wp-revision-192138024", "exactText": "The LEAD programme evaluated the efficacy and safety of liraglutide in patients with type 2 diabetes either as monotherapy (LEAD 3) or in combination with metformin (LEAD 2), glimepiride (LEAD 1), metformin and rosiglitazone (LEAD 4) or metformin and glimepiride (LEAD 5)", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "artifactId": "wp-revision-192138024", "exactText": "Liraglutide treatment resulted in around 40-50% of patients reaching the American Diabetes Association goal of HbA1c < 7% at study completion", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-however-among-the-patients-that-were-previously-treated-with", "artifactId": "wp-revision-192138024", "exactText": "However, among the patients that were previously treated with only a single oral antidiabetic drug, liraglutide treatment resulted in around 50-60% of patients reaching this goal", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-these-success-rates-were-the-result-of-an-hba1c-reduction-of", "artifactId": "wp-revision-192138024", "exactText": "These success rates were the result of an HbA1c reduction of approximately 1 to 1.5 percentage points", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-hba1c-was-sustained-for-up-to-12-months-of-liraglutide-thera", "artifactId": "wp-revision-192138024", "exactText": "HbA1c was sustained for up to 12 months of liraglutide therapy", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-the-hba1c-reduction-achieved-in-the-liraglutide-group-was-mo", "artifactId": "wp-revision-192138024", "exactText": "The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-furthermore-a-significant-improvement-in-systolic-blood-pres", "artifactId": "wp-revision-192138024", "exactText": "Furthermore, a significant improvement in systolic blood pressure and a reduction of body weight of between 3 and 4 kg were seen in patients treated with liraglutide when compared to patients treated with glimepiride", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-in-lead-2-liraglutide-treated-patients-achieved-blood-glucos", "artifactId": "wp-revision-192138024", "exactText": "In LEAD 2, liraglutide-treated patients achieved blood glucose control with low levels of hypoglycaemia similar to placebo, contrasting with the glimepiride-treated group where hypoglycaemia occurred in a larger number of patients", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-the-most-frequently-reported-adverse-event-during-liraglutid", "artifactId": "wp-revision-192138024", "exactText": "The most frequently reported adverse event during liraglutide treatment was nausea at an absolute level of between 5% and 20%", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm-novo-nordi", "artifactId": "wp-revision-192138024", "exactText": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]\nNovo Nordisk R&D Pipeline [http://www.novonordisk.net/press/rd_pipeline/rd_pipeline.asp?showid=5]", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" }, { "assertionId": "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen", "artifactId": "wp-revision-192143244", "exactText": "The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from thepancreatic beta cells", "location": { "section": "(lead)" }, "extractionMethod": "automated", "extractionConfidence": "high", "extractedAt": "2008-02-17", "epistemicStatus": "extracted" } ], "claimFamilies": [ { "familyId": "fam-sentence-1", "familyName": "Following subcutaneous administration, the protracted action...", "keyAssertions": [ "assert-following-subcutaneous-administration-the-protracted-action-", "assert-following-subcutaneous-administration-the-protracted-action-" ], "variants": [ { "variantId": "var-fam-sentence-1-1", "variantName": "Following subcutaneous administration, the protracted action...", "proposition": "Following subcutaneous administration, the protracted action profile is based on three mechanisms: binding to albumin and enzymatic stability towards the DPP-IV enzyme both of which result in a long plasma half-life, and self-association which results in a slow absorption", "provenance": { "sourceAssertionId": "assert-following-subcutaneous-administration-the-protracted-action-", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-1-2", "variantName": "Following subcutaneous administration, the protracted action...", "proposition": "Following subcutaneous administration, the protracted action profile is based on three mechanisms: binding to albumin and enzymatic stability towards the Dipeptidyl peptidase-4 enzyme both of which result in a long plasma half-life, and self-association which results in a slow absorption", "provenance": { "sourceAssertionId": "assert-following-subcutaneous-administration-the-protracted-action-", "artifactId": "wp-revision-192142806", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-1-1", "toVariantId": "var-fam-sentence-1-2", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-2", "familyName": "Liraglutide action is mediated via a specific interaction wi...", "keyAssertions": [ "assert-liraglutide-action-is-mediated-via-a-specific-interaction-wi" ], "variants": [ { "variantId": "var-fam-sentence-2-1", "variantName": "Liraglutide action is mediated via a specific interaction wi...", "proposition": "Liraglutide action is mediated via a specific interaction with GLP-1 receptors, leading to an increase in cAMP", "provenance": { "sourceAssertionId": "assert-liraglutide-action-is-mediated-via-a-specific-interaction-wi", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-3", "familyName": "Liraglutide stimulates insulin secretion and improves beta-c...", "keyAssertions": [ "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c", "assert-simultaneously-liraglutide-lowers-inappropriately-high-gluca", "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c" ], "variants": [ { "variantId": "var-fam-sentence-3-1", "variantName": "Liraglutide stimulates insulin secretion and improves beta-c...", "proposition": "Liraglutide stimulates insulin secretion and improves beta-cell function in a glucose-dependent manner", "provenance": { "sourceAssertionId": "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-2", "variantName": "Simultaneously, liraglutide lowers inappropriately high gluc...", "proposition": "Simultaneously, liraglutide lowers inappropriately high glucagon secretion, also in a glucose dependent manner", "provenance": { "sourceAssertionId": "assert-simultaneously-liraglutide-lowers-inappropriately-high-gluca", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-3", "variantName": "Liraglutide stimulates insulin secretion and improves beta-c...", "proposition": "Liraglutide stimulates insulin secretion and improves beta-cell function in a glucose dependent manner", "provenance": { "sourceAssertionId": "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-3-1", "toVariantId": "var-fam-sentence-3-2", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-3-2", "toVariantId": "var-fam-sentence-3-3", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-4", "familyName": "Thus, when blood glucose is high, insulin secretion is stimu...", "keyAssertions": [ "assert-thus-when-blood-glucose-is-high-insulin-secretion-is-stimula" ], "variants": [ { "variantId": "var-fam-sentence-4-1", "variantName": "Thus, when blood glucose is high, insulin secretion is stimu...", "proposition": "Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited", "provenance": { "sourceAssertionId": "assert-thus-when-blood-glucose-is-high-insulin-secretion-is-stimula", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-5", "familyName": "Liraglutide does not impair glucagon response during hypogly...", "keyAssertions": [ "assert-liraglutide-does-not-impair-glucagon-response-during-hypogly" ], "variants": [ { "variantId": "var-fam-sentence-5-1", "variantName": "Liraglutide does not impair glucagon response during hypogly...", "proposition": "Liraglutide does not impair glucagon response during hypoglycaemia", "provenance": { "sourceAssertionId": "assert-liraglutide-does-not-impair-glucagon-response-during-hypogly", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-6", "familyName": "Furthermore, the mechanism of blood glucose lowering involve...", "keyAssertions": [ "assert-furthermore-the-mechanism-of-blood-glucose-lowering-involves" ], "variants": [ { "variantId": "var-fam-sentence-6-1", "variantName": "Furthermore, the mechanism of blood glucose lowering involve...", "proposition": "Furthermore, the mechanism of blood glucose lowering involves a minor decrease in gastric emptying", "provenance": { "sourceAssertionId": "assert-furthermore-the-mechanism-of-blood-glucose-lowering-involves", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-7", "familyName": "Liraglutide reduces body weight and body fat mass, by a mech...", "keyAssertions": [ "assert-liraglutide-reduces-body-weight-and-body-fat-mass-by-a-mecha" ], "variants": [ { "variantId": "var-fam-sentence-7-1", "variantName": "Liraglutide reduces body weight and body fat mass, by a mech...", "proposition": "Liraglutide reduces body weight and body fat mass, by a mechanism of reduced hunger and lowered energy intake", "provenance": { "sourceAssertionId": "assert-liraglutide-reduces-body-weight-and-body-fat-mass-by-a-mecha", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-8", "familyName": "Liraglutide has been shown to delay the progression of diabe...", "keyAssertions": [ "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe", "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe" ], "variants": [ { "variantId": "var-fam-sentence-8-1", "variantName": "Liraglutide has been shown to delay the progression of diabe...", "proposition": "Liraglutide has been shown to delay the progression of diabetes in animal models of pre-diabetes", "provenance": { "sourceAssertionId": "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-8-2", "variantName": "Liraglutide has been shown to delay the progression of diabe...", "proposition": "Liraglutide has been shown to delay the progression of diabetes in animal models of prediabetes", "provenance": { "sourceAssertionId": "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-8-1", "toVariantId": "var-fam-sentence-8-2", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-9", "familyName": "Liraglutide has been shown in vitro to be a potent agent for...", "keyAssertions": [ "assert-liraglutide-has-been-shown-in-vitro-to-be-a-potent-agent-for" ], "variants": [ { "variantId": "var-fam-sentence-9-1", "variantName": "Liraglutide has been shown in vitro to be a potent agent for...", "proposition": "Liraglutide has been shown in vitro to be a potent agent for specific stimulation of beta-cell proliferation and prevention of both cytokine and free fatty acid induced apoptosis", "provenance": { "sourceAssertionId": "assert-liraglutide-has-been-shown-in-vitro-to-be-a-potent-agent-for", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-10", "familyName": "In vivo, liraglutide increases insulin biosynthesis, and bet...", "keyAssertions": [ "assert-in-vivo-liraglutide-increases-insulin-biosynthesis-and-beta-" ], "variants": [ { "variantId": "var-fam-sentence-10-1", "variantName": "In vivo, liraglutide increases insulin biosynthesis, and bet...", "proposition": "In vivo, liraglutide increases insulin biosynthesis, and beta-cell mass in diabetic animal models", "provenance": { "sourceAssertionId": "assert-in-vivo-liraglutide-increases-insulin-biosynthesis-and-beta-", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-11", "familyName": "References:\n[http://www.glucagon.com/liraglutide.htm]", "keyAssertions": [ "assert-references-http-www-glucagon-com-liraglutide-htm", "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm", "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm-novo-nordi" ], "variants": [ { "variantId": "var-fam-sentence-11-1", "variantName": "References:\n[http://www.glucagon.com/liraglutide.htm]", "proposition": "References:\n[http://www.glucagon.com/liraglutide.htm]", "provenance": { "sourceAssertionId": "assert-references-http-www-glucagon-com-liraglutide-htm", "artifactId": "wp-revision-192131328", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-11-2", "variantName": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]", "proposition": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]", "provenance": { "sourceAssertionId": "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm", "artifactId": "wp-revision-192132071", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-11-3", "variantName": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]\nNovo N...", "proposition": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]\nNovo Nordisk R&D Pipeline [http://www.novonordisk.net/press/rd_pipeline/rd_pipeline.asp?showid=5]", "provenance": { "sourceAssertionId": "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm-novo-nordi", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-11-1", "toVariantId": "var-fam-sentence-11-2", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-11-2", "toVariantId": "var-fam-sentence-11-3", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-12", "familyName": "In a phase 2 trial enrolling 165 patients with type 2 diabet...", "keyAssertions": [ "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet" ], "variants": [ { "variantId": "var-fam-sentence-12-1", "variantName": "In a phase 2 trial enrolling 165 patients with type 2 diabet...", "proposition": "In a phase 2 trial enrolling 165 patients with type 2 diabetes, 14 weeks of liraglutide monotherapy reduced the estimated mean HbA1c values by 1.74% vs placebo from an average baseline of 8.5% and FPG by 3.4 mmol/l without hypoglycemic episodes", "provenance": { "sourceAssertionId": "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "artifactId": "wp-revision-192133935", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-12-2", "variantName": "In a phase 2 trial enrolling 165 patients with type 2 diabet...", "proposition": "In a phase 2 trial enrolling 165 patients with type 2 diabetes, 14 weeks of liraglutide monotherapy reduced the estimated mean HbA1c values by 1.74% vs placebo from an average baseline of 8.5% and fasting plasma glucose by 3.4 mmol/l without hypoglycemic episodes", "provenance": { "sourceAssertionId": "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "artifactId": "wp-revision-192139472", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-12-3", "variantName": "In a phase 2 trial enrolling 165 patients with type 2 diabet...", "proposition": "In a phase 2 trial enrolling 165 patients with type 2 diabetes, 14 weeks of liraglutide monotherapy reduced the estimated mean HbA1c values by 1.74% vs placebo from an average baseline of 8.5% and fasting blood glucose by 3.4 mmol/l without hypoglycemic episodes", "provenance": { "sourceAssertionId": "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "artifactId": "wp-revision-192141705", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-12-1", "toVariantId": "var-fam-sentence-12-2", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-12-2", "toVariantId": "var-fam-sentence-12-3", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-13", "familyName": "A dose-dependent decrease in body weight was observed, with ...", "keyAssertions": [ "assert-a-dose-dependent-decrease-in-body-weight-was-observed-with-a" ], "variants": [ { "variantId": "var-fam-sentence-13-1", "variantName": "A dose-dependent decrease in body weight was observed, with ...", "proposition": "A dose-dependent decrease in body weight was observed, with a mean weight loss of 3.0 kg in the 1.9-mg liraglutide group", "provenance": { "sourceAssertionId": "assert-a-dose-dependent-decrease-in-body-weight-was-observed-with-a", "artifactId": "wp-revision-192133935", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-14", "familyName": "Significant improvements in indices of beta cell function an...", "keyAssertions": [ "assert-significant-improvements-in-indices-of-beta-cell-function-an", "assert-significant-improvements-in-indices-of-beta-cell-function-an", "assert-furthermore-a-significant-improvement-in-systolic-blood-pres" ], "variants": [ { "variantId": "var-fam-sentence-14-1", "variantName": "Significant improvements in indices of beta cell function an...", "proposition": "Significant improvements in indices of beta cell function and blood pressure were also found along with a decrease in fasting glucagon with lira 1.9 mg", "provenance": { "sourceAssertionId": "assert-significant-improvements-in-indices-of-beta-cell-function-an", "artifactId": "wp-revision-192133935", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-14-2", "variantName": "Significant improvements in indices of beta cell function an...", "proposition": "Significant improvements in indices of beta cell function and systolic blood pressure decrease of 2–3 mmHg were also found along with a decrease in fasting glucagon with lira 1.9 mg", "provenance": { "sourceAssertionId": "assert-significant-improvements-in-indices-of-beta-cell-function-an", "artifactId": "wp-revision-192135498", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-14-3", "variantName": "Furthermore, a significant improvement in systolic blood pre...", "proposition": "Furthermore, a significant improvement in systolic blood pressure and a reduction of body weight of between 3 and 4 kg were seen in patients treated with liraglutide when compared to patients treated with glimepiride", "provenance": { "sourceAssertionId": "assert-furthermore-a-significant-improvement-in-systolic-blood-pres", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-14-1", "toVariantId": "var-fam-sentence-14-2", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-14-2", "toVariantId": "var-fam-sentence-14-3", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-15", "familyName": "The LEAD programme evaluated the efficacy and safety of lira...", "keyAssertions": [ "assert-the-lead-programme-evaluated-the-efficacy-and-safety-of-lira" ], "variants": [ { "variantId": "var-fam-sentence-15-1", "variantName": "The LEAD programme evaluated the efficacy and safety of lira...", "proposition": "The LEAD programme evaluated the efficacy and safety of liraglutide in patients with type 2 diabetes either as monotherapy (LEAD 3) or in combination with metformin (LEAD 2), glimepiride (LEAD 1), metformin and rosiglitazone (LEAD 4) or metformin and glimepiride (LEAD 5)", "provenance": { "sourceAssertionId": "assert-the-lead-programme-evaluated-the-efficacy-and-safety-of-lira", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-16", "familyName": "Liraglutide treatment resulted in around 40-50% of patients ...", "keyAssertions": [ "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "assert-however-among-the-patients-that-were-previously-treated-with", "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r" ], "variants": [ { "variantId": "var-fam-sentence-16-1", "variantName": "Liraglutide treatment resulted in around 40-50% of patients ...", "proposition": "Liraglutide treatment resulted in around 40-50% of patients reaching the American Diabetes Association goal of HbA1c < 7% at study completion", "provenance": { "sourceAssertionId": "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-16-2", "variantName": "However, among the patients that were previously treated wit...", "proposition": "However, among the patients that were previously treated with only a single oral antidiabetic drug, liraglutide treatment resulted in around 50-60% of patients reaching this goal", "provenance": { "sourceAssertionId": "assert-however-among-the-patients-that-were-previously-treated-with", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-16-3", "variantName": "Liraglutide treatment resulted in around 40-50% of patients ...", "proposition": "Liraglutide treatment resulted in around 40-50% of patients reaching the American Diabetes Association goal of HbA1c \nNovo Nordisk R&D Pipeline [http://www.novonordisk.net/press/rd_pipeline/rd_pipeline.asp?showid=5]", "provenance": { "sourceAssertionId": "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "artifactId": "wp-revision-192138737", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-16-4", "variantName": "Liraglutide treatment resulted in around 40-50% of patients ...", "proposition": "Liraglutide treatment resulted in around 40-50% of patients reaching the American Diabetes Association goal of HbA1c \nDr D", "provenance": { "sourceAssertionId": "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-16-1", "toVariantId": "var-fam-sentence-16-2", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-16-2", "toVariantId": "var-fam-sentence-16-3", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" }, { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-16-3", "toVariantId": "var-fam-sentence-16-4", "confidence": "medium", "relationshipBasis": "Content change: introduction", "epistemicStatus": "inferred" } ] }, { "familyId": "fam-sentence-17", "familyName": "These success rates were the result of an HbA1c reduction of...", "keyAssertions": [ "assert-these-success-rates-were-the-result-of-an-hba1c-reduction-of" ], "variants": [ { "variantId": "var-fam-sentence-17-1", "variantName": "These success rates were the result of an HbA1c reduction of...", "proposition": "These success rates were the result of an HbA1c reduction of approximately 1 to 1.5 percentage points", "provenance": { "sourceAssertionId": "assert-these-success-rates-were-the-result-of-an-hba1c-reduction-of", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-18", "familyName": "HbA1c was sustained for up to 12 months of liraglutide thera...", "keyAssertions": [ "assert-hba1c-was-sustained-for-up-to-12-months-of-liraglutide-thera" ], "variants": [ { "variantId": "var-fam-sentence-18-1", "variantName": "HbA1c was sustained for up to 12 months of liraglutide thera...", "proposition": "HbA1c was sustained for up to 12 months of liraglutide therapy", "provenance": { "sourceAssertionId": "assert-hba1c-was-sustained-for-up-to-12-months-of-liraglutide-thera", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-19", "familyName": "The HbA1c reduction achieved in the liraglutide group was mo...", "keyAssertions": [ "assert-the-hba1c-reduction-achieved-in-the-liraglutide-group-was-mo" ], "variants": [ { "variantId": "var-fam-sentence-19-1", "variantName": "The HbA1c reduction achieved in the liraglutide group was mo...", "proposition": "The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant", "provenance": { "sourceAssertionId": "assert-the-hba1c-reduction-achieved-in-the-liraglutide-group-was-mo", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-20", "familyName": "In LEAD 2, liraglutide-treated patients achieved blood gluco...", "keyAssertions": [ "assert-in-lead-2-liraglutide-treated-patients-achieved-blood-glucos" ], "variants": [ { "variantId": "var-fam-sentence-20-1", "variantName": "In LEAD 2, liraglutide-treated patients achieved blood gluco...", "proposition": "In LEAD 2, liraglutide-treated patients achieved blood glucose control with low levels of hypoglycaemia similar to placebo, contrasting with the glimepiride-treated group where hypoglycaemia occurred in a larger number of patients", "provenance": { "sourceAssertionId": "assert-in-lead-2-liraglutide-treated-patients-achieved-blood-glucos", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-21", "familyName": "The most frequently reported adverse event during liraglutid...", "keyAssertions": [ "assert-the-most-frequently-reported-adverse-event-during-liraglutid" ], "variants": [ { "variantId": "var-fam-sentence-21-1", "variantName": "The most frequently reported adverse event during liraglutid...", "proposition": "The most frequently reported adverse event during liraglutide treatment was nausea at an absolute level of between 5% and 20%", "provenance": { "sourceAssertionId": "assert-the-most-frequently-reported-adverse-event-during-liraglutid", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [] }, { "familyId": "fam-sentence-22", "familyName": "The GLP-1 receptor is the target for native GLP-1, an endoge...", "keyAssertions": [ "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen", "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen" ], "variants": [ { "variantId": "var-fam-sentence-22-1", "variantName": "The GLP-1 receptor is the target for native GLP-1, an endoge...", "proposition": "The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from thepancreatic beta cells", "provenance": { "sourceAssertionId": "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen", "artifactId": "wp-revision-192143244", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-22-2", "variantName": "The GLP-1 receptor is the target for native GLP-1, an endoge...", "proposition": "The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells", "provenance": { "sourceAssertionId": "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relationships": [ { "relationshipType": "qualifies", "fromVariantId": "var-fam-sentence-22-1", "toVariantId": "var-fam-sentence-22-2", "confidence": "medium", "relationshipBasis": "Content change: refinement", "epistemicStatus": "inferred" } ] } ], "claimVariants": [ { "variantId": "var-fam-sentence-1-1", "variantName": "Following subcutaneous administration, the protracted action...", "proposition": "Following subcutaneous administration, the protracted action profile is based on three mechanisms: binding to albumin and enzymatic stability towards the DPP-IV enzyme both of which result in a long plasma half-life, and self-association which results in a slow absorption", "provenance": { "sourceAssertionId": "assert-following-subcutaneous-administration-the-protracted-action-", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-1-2", "variantName": "Following subcutaneous administration, the protracted action...", "proposition": "Following subcutaneous administration, the protracted action profile is based on three mechanisms: binding to albumin and enzymatic stability towards the Dipeptidyl peptidase-4 enzyme both of which result in a long plasma half-life, and self-association which results in a slow absorption", "provenance": { "sourceAssertionId": "assert-following-subcutaneous-administration-the-protracted-action-", "artifactId": "wp-revision-192142806", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-2-1", "variantName": "Liraglutide action is mediated via a specific interaction wi...", "proposition": "Liraglutide action is mediated via a specific interaction with GLP-1 receptors, leading to an increase in cAMP", "provenance": { "sourceAssertionId": "assert-liraglutide-action-is-mediated-via-a-specific-interaction-wi", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-1", "variantName": "Liraglutide stimulates insulin secretion and improves beta-c...", "proposition": "Liraglutide stimulates insulin secretion and improves beta-cell function in a glucose-dependent manner", "provenance": { "sourceAssertionId": "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-2", "variantName": "Simultaneously, liraglutide lowers inappropriately high gluc...", "proposition": "Simultaneously, liraglutide lowers inappropriately high glucagon secretion, also in a glucose dependent manner", "provenance": { "sourceAssertionId": "assert-simultaneously-liraglutide-lowers-inappropriately-high-gluca", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-3-3", "variantName": "Liraglutide stimulates insulin secretion and improves beta-c...", "proposition": "Liraglutide stimulates insulin secretion and improves beta-cell function in a glucose dependent manner", "provenance": { "sourceAssertionId": "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-4-1", "variantName": "Thus, when blood glucose is high, insulin secretion is stimu...", "proposition": "Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited", "provenance": { "sourceAssertionId": "assert-thus-when-blood-glucose-is-high-insulin-secretion-is-stimula", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-5-1", "variantName": "Liraglutide does not impair glucagon response during hypogly...", "proposition": "Liraglutide does not impair glucagon response during hypoglycaemia", "provenance": { "sourceAssertionId": "assert-liraglutide-does-not-impair-glucagon-response-during-hypogly", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-6-1", "variantName": "Furthermore, the mechanism of blood glucose lowering involve...", "proposition": "Furthermore, the mechanism of blood glucose lowering involves a minor decrease in gastric emptying", "provenance": { "sourceAssertionId": "assert-furthermore-the-mechanism-of-blood-glucose-lowering-involves", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-7-1", "variantName": "Liraglutide reduces body weight and body fat mass, by a mech...", "proposition": "Liraglutide reduces body weight and body fat mass, by a mechanism of reduced hunger and lowered energy intake", "provenance": { "sourceAssertionId": "assert-liraglutide-reduces-body-weight-and-body-fat-mass-by-a-mecha", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-8-1", "variantName": "Liraglutide has been shown to delay the progression of diabe...", "proposition": "Liraglutide has been shown to delay the progression of diabetes in animal models of pre-diabetes", "provenance": { "sourceAssertionId": "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-8-2", "variantName": "Liraglutide has been shown to delay the progression of diabe...", "proposition": "Liraglutide has been shown to delay the progression of diabetes in animal models of prediabetes", "provenance": { "sourceAssertionId": "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-9-1", "variantName": "Liraglutide has been shown in vitro to be a potent agent for...", "proposition": "Liraglutide has been shown in vitro to be a potent agent for specific stimulation of beta-cell proliferation and prevention of both cytokine and free fatty acid induced apoptosis", "provenance": { "sourceAssertionId": "assert-liraglutide-has-been-shown-in-vitro-to-be-a-potent-agent-for", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-10-1", "variantName": "In vivo, liraglutide increases insulin biosynthesis, and bet...", "proposition": "In vivo, liraglutide increases insulin biosynthesis, and beta-cell mass in diabetic animal models", "provenance": { "sourceAssertionId": "assert-in-vivo-liraglutide-increases-insulin-biosynthesis-and-beta-", "artifactId": "wp-revision-192123901", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-11-1", "variantName": "References:\n[http://www.glucagon.com/liraglutide.htm]", "proposition": "References:\n[http://www.glucagon.com/liraglutide.htm]", "provenance": { "sourceAssertionId": "assert-references-http-www-glucagon-com-liraglutide-htm", "artifactId": "wp-revision-192131328", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-11-2", "variantName": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]", "proposition": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]", "provenance": { "sourceAssertionId": "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm", "artifactId": "wp-revision-192132071", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-11-3", "variantName": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]\nNovo N...", "proposition": "Drucker Lab [http://www.glucagon.com/liraglutide.htm]\nNovo Nordisk R&D Pipeline [http://www.novonordisk.net/press/rd_pipeline/rd_pipeline.asp?showid=5]", "provenance": { "sourceAssertionId": "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm-novo-nordi", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-12-1", "variantName": "In a phase 2 trial enrolling 165 patients with type 2 diabet...", "proposition": "In a phase 2 trial enrolling 165 patients with type 2 diabetes, 14 weeks of liraglutide monotherapy reduced the estimated mean HbA1c values by 1.74% vs placebo from an average baseline of 8.5% and FPG by 3.4 mmol/l without hypoglycemic episodes", "provenance": { "sourceAssertionId": "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "artifactId": "wp-revision-192133935", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-12-2", "variantName": "In a phase 2 trial enrolling 165 patients with type 2 diabet...", "proposition": "In a phase 2 trial enrolling 165 patients with type 2 diabetes, 14 weeks of liraglutide monotherapy reduced the estimated mean HbA1c values by 1.74% vs placebo from an average baseline of 8.5% and fasting plasma glucose by 3.4 mmol/l without hypoglycemic episodes", "provenance": { "sourceAssertionId": "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "artifactId": "wp-revision-192139472", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-12-3", "variantName": "In a phase 2 trial enrolling 165 patients with type 2 diabet...", "proposition": "In a phase 2 trial enrolling 165 patients with type 2 diabetes, 14 weeks of liraglutide monotherapy reduced the estimated mean HbA1c values by 1.74% vs placebo from an average baseline of 8.5% and fasting blood glucose by 3.4 mmol/l without hypoglycemic episodes", "provenance": { "sourceAssertionId": "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "artifactId": "wp-revision-192141705", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-13-1", "variantName": "A dose-dependent decrease in body weight was observed, with ...", "proposition": "A dose-dependent decrease in body weight was observed, with a mean weight loss of 3.0 kg in the 1.9-mg liraglutide group", "provenance": { "sourceAssertionId": "assert-a-dose-dependent-decrease-in-body-weight-was-observed-with-a", "artifactId": "wp-revision-192133935", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-14-1", "variantName": "Significant improvements in indices of beta cell function an...", "proposition": "Significant improvements in indices of beta cell function and blood pressure were also found along with a decrease in fasting glucagon with lira 1.9 mg", "provenance": { "sourceAssertionId": "assert-significant-improvements-in-indices-of-beta-cell-function-an", "artifactId": "wp-revision-192133935", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-14-2", "variantName": "Significant improvements in indices of beta cell function an...", "proposition": "Significant improvements in indices of beta cell function and systolic blood pressure decrease of 2–3 mmHg were also found along with a decrease in fasting glucagon with lira 1.9 mg", "provenance": { "sourceAssertionId": "assert-significant-improvements-in-indices-of-beta-cell-function-an", "artifactId": "wp-revision-192135498", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-14-3", "variantName": "Furthermore, a significant improvement in systolic blood pre...", "proposition": "Furthermore, a significant improvement in systolic blood pressure and a reduction of body weight of between 3 and 4 kg were seen in patients treated with liraglutide when compared to patients treated with glimepiride", "provenance": { "sourceAssertionId": "assert-furthermore-a-significant-improvement-in-systolic-blood-pres", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-15-1", "variantName": "The LEAD programme evaluated the efficacy and safety of lira...", "proposition": "The LEAD programme evaluated the efficacy and safety of liraglutide in patients with type 2 diabetes either as monotherapy (LEAD 3) or in combination with metformin (LEAD 2), glimepiride (LEAD 1), metformin and rosiglitazone (LEAD 4) or metformin and glimepiride (LEAD 5)", "provenance": { "sourceAssertionId": "assert-the-lead-programme-evaluated-the-efficacy-and-safety-of-lira", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-16-1", "variantName": "Liraglutide treatment resulted in around 40-50% of patients ...", "proposition": "Liraglutide treatment resulted in around 40-50% of patients reaching the American Diabetes Association goal of HbA1c < 7% at study completion", "provenance": { "sourceAssertionId": "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-16-2", "variantName": "However, among the patients that were previously treated wit...", "proposition": "However, among the patients that were previously treated with only a single oral antidiabetic drug, liraglutide treatment resulted in around 50-60% of patients reaching this goal", "provenance": { "sourceAssertionId": "assert-however-among-the-patients-that-were-previously-treated-with", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-16-3", "variantName": "Liraglutide treatment resulted in around 40-50% of patients ...", "proposition": "Liraglutide treatment resulted in around 40-50% of patients reaching the American Diabetes Association goal of HbA1c \nNovo Nordisk R&D Pipeline [http://www.novonordisk.net/press/rd_pipeline/rd_pipeline.asp?showid=5]", "provenance": { "sourceAssertionId": "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "artifactId": "wp-revision-192138737", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-16-4", "variantName": "Liraglutide treatment resulted in around 40-50% of patients ...", "proposition": "Liraglutide treatment resulted in around 40-50% of patients reaching the American Diabetes Association goal of HbA1c \nDr D", "provenance": { "sourceAssertionId": "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-17-1", "variantName": "These success rates were the result of an HbA1c reduction of...", "proposition": "These success rates were the result of an HbA1c reduction of approximately 1 to 1.5 percentage points", "provenance": { "sourceAssertionId": "assert-these-success-rates-were-the-result-of-an-hba1c-reduction-of", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-18-1", "variantName": "HbA1c was sustained for up to 12 months of liraglutide thera...", "proposition": "HbA1c was sustained for up to 12 months of liraglutide therapy", "provenance": { "sourceAssertionId": "assert-hba1c-was-sustained-for-up-to-12-months-of-liraglutide-thera", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-19-1", "variantName": "The HbA1c reduction achieved in the liraglutide group was mo...", "proposition": "The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant", "provenance": { "sourceAssertionId": "assert-the-hba1c-reduction-achieved-in-the-liraglutide-group-was-mo", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-20-1", "variantName": "In LEAD 2, liraglutide-treated patients achieved blood gluco...", "proposition": "In LEAD 2, liraglutide-treated patients achieved blood glucose control with low levels of hypoglycaemia similar to placebo, contrasting with the glimepiride-treated group where hypoglycaemia occurred in a larger number of patients", "provenance": { "sourceAssertionId": "assert-in-lead-2-liraglutide-treated-patients-achieved-blood-glucos", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-21-1", "variantName": "The most frequently reported adverse event during liraglutid...", "proposition": "The most frequently reported adverse event during liraglutide treatment was nausea at an absolute level of between 5% and 20%", "provenance": { "sourceAssertionId": "assert-the-most-frequently-reported-adverse-event-during-liraglutid", "artifactId": "wp-revision-192138024", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-22-1", "variantName": "The GLP-1 receptor is the target for native GLP-1, an endoge...", "proposition": "The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from thepancreatic beta cells", "provenance": { "sourceAssertionId": "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen", "artifactId": "wp-revision-192143244", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" }, { "variantId": "var-fam-sentence-22-2", "variantName": "The GLP-1 receptor is the target for native GLP-1, an endoge...", "proposition": "The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells", "provenance": { "sourceAssertionId": "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen", "artifactId": "wp-revision-192145258", "location": { "section": "(lead)" }, "extractedAt": "2008-02-17", "extractionMethod": "automated", "extractionConfidence": "high" }, "hasSupportingEvidence": true, "epistemicStatus": "normalized" } ], "relianceCommitments": [ { "commitmentId": "rely-cit-192131328-1", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "Wikipedia", "sourceArtifact": { "artifactType": "other", "issuer": "care.diabetesjournals.org", "title": "http://care.diabetesjournals.org/cgi/content/full/25/8/1398", "stableIdentifier": "http://care.diabetesjournals.org/cgi/content/full/25/8/1398" }, "commitmentDate": "2008-02-17", "confidence": "medium", "rationale": "citation_added in revision 192131328", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-192131328-2", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "Wikipedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.medscape.com", "title": "http://www.medscape.com/viewarticle/551640", "stableIdentifier": "http://www.medscape.com/viewarticle/551640" }, "commitmentDate": "2008-02-17", "confidence": "medium", "rationale": "citation_added in revision 192131328", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-192131328-3", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "Wikipedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.medpagetoday.com", "title": "http://www.medpagetoday.com/MeetingCoverage/AACE/tb/5480", "stableIdentifier": "http://www.medpagetoday.com/MeetingCoverage/AACE/tb/5480" }, "commitmentDate": "2008-02-17", "confidence": "medium", "rationale": "citation_added in revision 192131328", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-192131328-4", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "Wikipedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.glucagon.com", "title": "http://www.glucagon.com/liraglutide.htm", "stableIdentifier": "http://www.glucagon.com/liraglutide.htm" }, "commitmentDate": "2008-02-17", "confidence": "medium", "rationale": "citation_removed in revision 192131328", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-192133935-5", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "Wikipedia", "sourceArtifact": { "artifactType": "other", "issuer": "care.diabetesjournals.org", "title": "http://care.diabetesjournals.org/cgi/content/full/30/6/1608", "stableIdentifier": "http://care.diabetesjournals.org/cgi/content/full/30/6/1608" }, "commitmentDate": "2008-02-17", "confidence": "medium", "rationale": "citation_added in revision 192133935", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-192138024-6", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "Wikipedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.novonordisk.net", "title": "http://www.novonordisk.net/press/sea/sea.asp?sNewsTypeGUID=&lMonth=0&lYear=2007&sLanguageCode=en-GB&sSearchText=liraglutide&sShowNewsItemGUID=0611b01a-e3c2-4ea4-9986-c28247e5021c&sShowLanguageCode=en-GB", "stableIdentifier": "http://www.novonordisk.net/press/sea/sea.asp?sNewsTypeGUID=&lMonth=0&lYear=2007&sLanguageCode=en-GB&sSearchText=liraglutide&sShowNewsItemGUID=0611b01a-e3c2-4ea4-9986-c28247e5021c&sShowLanguageCode=en-GB" }, "commitmentDate": "2008-02-17", "confidence": "medium", "rationale": "citation_added in revision 192138024", "epistemicStatus": "inferred" }, { "commitmentId": "rely-cit-192138024-7", "claimVariantId": "", "commitmentType": "reference", "committingInstitution": "Wikipedia", "sourceArtifact": { "artifactType": "other", "issuer": "www.novonordisk.net", "title": "http://www.novonordisk.net/press/sea/sea.asp?sNewsTypeGUID=&lMonth=0&lYear=2007&sLanguageCode=en-GB&sSearchText=liraglutide&sShowNewsItemGUID=200a7488-b399-4a27-b379-9250effdfe30&sShowLanguageCode=en-GB", "stableIdentifier": "http://www.novonordisk.net/press/sea/sea.asp?sNewsTypeGUID=&lMonth=0&lYear=2007&sLanguageCode=en-GB&sSearchText=liraglutide&sShowNewsItemGUID=200a7488-b399-4a27-b379-9250effdfe30&sShowLanguageCode=en-GB" }, "commitmentDate": "2008-02-17", "confidence": "medium", "rationale": "citation_added in revision 192138024", "epistemicStatus": "inferred" }, { "epistemicStatus": "institution-confirmed", "commitmentId": "rely-fda-liraglutide-t2d", "claimVariantId": "var-fam-sentence-3-1", "commitmentType": "operational-use", "committingInstitution": "FDA", "sourceArtifact": { "artifactType": "regulatory", "issuer": "U.S. Food and Drug Administration", "title": "Liraglutide (Victoza) approval for type 2 diabetes, NDA 022341", "stableIdentifier": "https://www.accessdata.fda.gov/drugsatfda_docs/applets/2010/022341s000TOC.cfm" }, "commitmentDate": "2010-01-25", "confidence": "high", "rationale": "FDA approval operationalizes the claim that liraglutide stimulates insulin secretion and improves glycemic control in type 2 diabetes." }, { "epistemicStatus": "institution-confirmed", "commitmentId": "rely-fda-liraglutide-obesity", "claimVariantId": "var-fam-sentence-7-1", "commitmentType": "operational-use", "committingInstitution": "FDA", "sourceArtifact": { "artifactType": "regulatory", "issuer": "U.S. Food and Drug Administration", "title": "Liraglutide (Saxenda) approval for chronic weight management, NDA 206321", "stableIdentifier": "https://www.accessdata.fda.gov/drugsatfda_docs/applets/2014/206321Orig1s000TOC.cfm" }, "commitmentDate": "2014-12-23", "confidence": "high", "rationale": "FDA approval for chronic weight management operationalizes the claim that liraglutide reduces body weight and fat mass." }, { "epistemicStatus": "inferred", "commitmentId": "rely-ada-liraglutide-ascvd", "claimVariantId": "var-fam-sentence-3-1", "commitmentType": "endorsement", "committingInstitution": "American Diabetes Association", "sourceArtifact": { "artifactType": "guideline", "issuer": "American Diabetes Association", "title": "Standards of Care in Diabetes — Glycemic Goals", "stableIdentifier": "https://diabetesjournals.org/care/issue/47/Supplement_1" }, "commitmentDate": "2024-01-01", "confidence": "medium", "rationale": "ADA Standards of Care endorse liraglutide and other GLP-1 receptor agonists for type 2 diabetes, particularly when ASCVD is present." } ], "observedEvents": [ { "eventId": "evt-fda-liraglutide-t2d", "eventType": "artifact-issued", "title": "FDA approves liraglutide for type 2 diabetes", "description": "FDA approves liraglutide (Victoza) for improving glycemic control in adults with type 2 diabetes.", "occurredAt": "2010-01-25", "jurisdiction": "United States", "epistemicStatus": "directly-observed" }, { "eventId": "evt-fda-liraglutide-obesity", "eventType": "artifact-issued", "title": "FDA approves liraglutide for chronic weight management", "description": "FDA approves liraglutide (Saxenda) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.", "occurredAt": "2014-12-23", "jurisdiction": "United States", "epistemicStatus": "directly-observed" }, { "eventId": "evt-ada-liraglutide-endorsement", "eventType": "guideline-updated", "title": "ADA Standards of Care endorse liraglutide class", "description": "American Diabetes Association Standards of Care recommend liraglutide and other GLP-1 receptor agonists for type 2 diabetes with ASCVD.", "occurredAt": "2024-01-01", "jurisdiction": "United States", "epistemicStatus": "directly-observed" } ], "eventImpacts": [ { "impactId": "impact-fam-sentence-1-modification", "claimFamilyId": "fam-sentence-1", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-following-subcutaneous-administration-the-protracted-action-", "assert-following-subcutaneous-administration-the-protracted-action-" ], "analysisDescription": "2 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-3-modification", "claimFamilyId": "fam-sentence-3", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c", "assert-simultaneously-liraglutide-lowers-inappropriately-high-gluca", "assert-liraglutide-stimulates-insulin-secretion-and-improves-beta-c" ], "analysisDescription": "3 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-8-modification", "claimFamilyId": "fam-sentence-8", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe", "assert-liraglutide-has-been-shown-to-delay-the-progression-of-diabe" ], "analysisDescription": "2 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-11-modification", "claimFamilyId": "fam-sentence-11", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-references-http-www-glucagon-com-liraglutide-htm", "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm", "assert-drucker-lab-http-www-glucagon-com-liraglutide-htm-novo-nordi" ], "analysisDescription": "3 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-12-modification", "claimFamilyId": "fam-sentence-12", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet", "assert-in-a-phase-2-trial-enrolling-165-patients-with-type-2-diabet" ], "analysisDescription": "3 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-14-modification", "claimFamilyId": "fam-sentence-14", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-significant-improvements-in-indices-of-beta-cell-function-an", "assert-significant-improvements-in-indices-of-beta-cell-function-an", "assert-furthermore-a-significant-improvement-in-systolic-blood-pres" ], "analysisDescription": "3 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-16-modification", "claimFamilyId": "fam-sentence-16", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "assert-however-among-the-patients-that-were-previously-treated-with", "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r", "assert-liraglutide-treatment-resulted-in-around-40-50-of-patients-r" ], "analysisDescription": "4 variants detected across revision history", "epistemicStatus": "inferred" }, { "impactId": "impact-fam-sentence-22-modification", "claimFamilyId": "fam-sentence-22", "eventId": "", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen", "assert-the-glp-1-receptor-is-the-target-for-native-glp-1-an-endogen" ], "analysisDescription": "2 variants detected across revision history", "epistemicStatus": "inferred" }, { "epistemicStatus": "inferred", "impactId": "impact-fda-liraglutide-t2d-fam-3", "claimFamilyId": "fam-sentence-3", "eventId": "evt-fda-liraglutide-t2d", "impactType": "support-enhanced", "confidence": "high", "evidentiaryBasis": [ "rely-fda-liraglutide-t2d" ], "analysisDescription": "FDA approval strengthens the claim that liraglutide stimulates insulin secretion and improves beta-cell function in T2D." }, { "epistemicStatus": "inferred", "impactId": "impact-fda-liraglutide-obesity-fam-7", "claimFamilyId": "fam-sentence-7", "eventId": "evt-fda-liraglutide-obesity", "impactType": "support-enhanced", "confidence": "high", "evidentiaryBasis": [ "rely-fda-liraglutide-obesity" ], "analysisDescription": "FDA approval for chronic weight management supports the claim that liraglutide reduces body weight and fat mass." }, { "epistemicStatus": "inferred", "impactId": "impact-ada-liraglutide-fam-3", "claimFamilyId": "fam-sentence-3", "eventId": "evt-ada-liraglutide-endorsement", "impactType": "support-enhanced", "confidence": "medium", "evidentiaryBasis": [ "rely-ada-liraglutide-ascvd" ], "analysisDescription": "ADA endorsement adds guideline support to the T2D claim, with ASCVD qualification." } ], "reviewDecisions": [ { "epistemicStatus": "analyst-asserted", "decisionId": "decision-fda-liraglutide-t2d-adopt", "claimFamilyId": "fam-sentence-3", "eventId": "evt-fda-liraglutide-t2d", "decisionType": "adopt", "rationale": "FDA approval provides direct operationalization for the T2D mechanism claim.", "inputs": [ "impact-fda-liraglutide-t2d-fam-3", "rely-fda-liraglutide-t2d" ], "decidedAt": "2010-01-25", "decidedBy": "automated reviewer", "confident": true }, { "epistemicStatus": "analyst-asserted", "decisionId": "decision-fda-liraglutide-obesity-narrow", "claimFamilyId": "fam-sentence-7", "eventId": "evt-fda-liraglutide-obesity", "decisionType": "amend", "rationale": "FDA obesity approval narrows the weight-loss claim from observational to approved indication without changing the family scope.", "inputs": [ "impact-fda-liraglutide-obesity-fam-7", "rely-fda-liraglutide-obesity" ], "decidedAt": "2014-12-23", "decidedBy": "automated reviewer", "confident": true }, { "epistemicStatus": "analyst-asserted", "decisionId": "decision-ada-liraglutide-retain", "claimFamilyId": "fam-sentence-3", "eventId": "evt-ada-liraglutide-endorsement", "decisionType": "retain-with-caveats", "rationale": "ADA endorsement supports the claim but is inferred from guideline language; retain with ASCVD qualification.", "inputs": [ "impact-ada-liraglutide-fam-3", "rely-ada-liraglutide-ascvd" ], "decidedAt": "2024-01-01", "decidedBy": "automated reviewer", "confident": false } ], "assessments": [ { "familyId": "fam-sentence-1", "direction": "stable", "confidence": "low", "variantCount": 2, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "2 variants, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-2", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-3", "direction": "stable", "confidence": "low", "variantCount": 3, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "3 variants, qualifies, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-4", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-5", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-6", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-7", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-8", "direction": "stable", "confidence": "low", "variantCount": 2, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "2 variants, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-9", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-10", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-11", "direction": "stable", "confidence": "low", "variantCount": 3, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "3 variants, qualifies, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-12", "direction": "stable", "confidence": "low", "variantCount": 3, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "3 variants, qualifies, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-13", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-14", "direction": "stable", "confidence": "low", "variantCount": 3, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "3 variants, qualifies, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-15", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-16", "direction": "stable", "confidence": "low", "variantCount": 4, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "4 variants, qualifies, qualifies, qualifies", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-17", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-18", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-19", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-20", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-21", "direction": "stable", "confidence": "medium", "variantCount": 1, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "1 variants, no relationships", "epistemicStatus": "analyst-asserted" }, { "familyId": "fam-sentence-22", "direction": "stable", "confidence": "low", "variantCount": 2, "netDirection": 0, "disputeCount": 0, "lastChangeAt": "2008-02-17", "summary": "2 variants, qualifies", "epistemicStatus": "analyst-asserted" } ] }, "classification": { "evidentiaryFields": [ "Public encyclopedia version identifiers", "Edit timestamps", "Editor usernames", "Edit comments", "Citation URLs", "Page move records", "Template changes" ], "derivedFields": [ "Sentence-level diffs (before/after)", "Citation added/removed events", "Section reorganization events", "Edit magnitude (minor/moderate/major)", "Content change type", "Key terms extraction", "Direction signal (strengthening/weakening/neutral)" ], "inferredFields": [ "Claim family membership", "Claim variant relationships", "Confidence assignment", "Impact direction", "Decision rationale reconstruction", "Reliance commitment interpretation" ], "illustrativeFields": [] }, "reproducibility": { "analysts": 1, "method": "Single-analyst automated reconstruction. Two-analyst reproducibility validation has not yet been performed on this specimen.", "familyOverlap": { "matched": 0, "total": 0, "ratio": 0 }, "variantOverlap": { "matched": 0, "total": 0, "ratio": 0 }, "documentedDisagreements": [], "passed": false }, "crossSpecimenImpacts": [ { "impactId": "cross-liraglutide-glp1-obesity", "direction": "outgoing", "targetSpecimenRoute": "/baselines/provenance/glp1/", "targetSpecimenTitle": "GLP-1 receptor agonist (public encyclopedia provenance reconstruction)", "targetClaimFamilyId": "fam-sentence-2", "sourceEventId": "evt-fda-liraglutide-obesity", "impactType": "scope-broadened", "confidence": "high", "rationale": "FDA approval of liraglutide for chronic weight management broadens the GLP-1 class claim about licensed indications, adding obesity/weight-management to the class narrative.", "sourceEventTitle": "FDA approves liraglutide for chronic weight management" }, { "impactId": "cross-liraglutide-glp1-t2d", "direction": "incoming", "targetSpecimenRoute": "/baselines/provenance/glp1/", "targetSpecimenTitle": "GLP-1 receptor agonist (public encyclopedia provenance reconstruction)", "targetClaimFamilyId": "fam-sentence-3", "sourceEventId": "evt-ada-liraglutide-endorsement", "impactType": "support-enhanced", "confidence": "medium", "rationale": "The GLP-1 class ADA endorsement inferred in the GLP-1 specimen also supports liraglutide's T2D claim, demonstrating how class-level institutional reliance propagates to member drugs.", "sourceEventTitle": "ADA Standards of Care endorse liraglutide class" } ] }